Almost one third of the new therapeutics approved by the FDA between 2001 and 2010 were affected by a postmarket safety event, according to a recent study conducted at Brigham and Women’s Hospital in Boston, Massachusetts.


  1. Downing NS, Shah ND, Aminawung JA, et al. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA. 2017;317(18):1854-1863. doi:10.1001/jama.2017.5150